Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.
Ahn H., Kim H., Yoon Y., Jeong M., Lee S., Chen P.
Prospective Study on Face & Skin, Hip, published in J Adv Res (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Adv Res (2025)
- Country
- Egypt
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40617409
- DOI
- 10.1016/j.jare.2025.07.001
Abstract (original English)
Cancer cachexia is a multifaceted metabolic syndrome characterized by severe loss of skeletal muscle and adipose tissue, diminishing both quality of life and survival in cancer patients. Despite its prevalence, effective treatments for cancer cachexia remain limited. The JAK/STAT signaling pathway has been identified as a key driver of muscle atrophy in cachexia. This study aimed to investigate the therapeutic potential of scutellarein, a natural compound, as a JAK kinase inhibitor to prevent and mitigate cancer cachexia-induced muscle atrophy. In vitro experiments were conducted using the mouse myoblast cell line C2C12 and human induced pluripotent stem cell (hiPSC)-derived skeletal muscle cells. Myotube atrophy was induced using IFN-γ/TNF-α and cancer cell-conditioned media. Two independent mouse models of cancer cachexia were utilized for in vivo analysis. Muscle tissues were examined through transcriptomic and molecular analyses, including RNA sequencing, PCR, and immunoblotting. Structure-activity relationship studies and molecular docking analyses were performed to investigate the binding interaction of scutellarein with JAK kinases. Through a chemical library screen, we identified scutellarein as a potent JAK kinase inhibitor. Scutellarein effectively mitigated myotube atrophy by inhibiting protein degradation and promoting protein synthesis in C2C12 and hiPSC-derived mu
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Oncologic safety of autologous fat grafting in head and neck cancer patients: A scoping review.
Systematic Review with a reported sample of 116 on Face & Skin, published in Med Oral Patol Oral Cir Bucal (2026) — summary generated from the PubMed abstract.
- 2026
- n = 116
Med Oral Patol Oral Cir Bucal - Level ASystematic ReviewEurope PMC
Stem cell-derived exosomes in tissue regeneration of oral and maxillofacial region: A systematic review
Systematic Review on Chronic Wound, published in Medicine (Baltimore) (2026) — summary generated from the PubMed abstract.
- 2026
Medicine (Baltimore) - Level AMeta-analysisPubMed
Stromal Vascular Fraction-Assisted Fat Grafting: A Systematic Review and Meta-analysis of Clinical Outcomes.
Meta-analysis on Face & Skin, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.
- 2026
Aesthetic Plast Surg - Level ASystematic ReviewEurope PMC
Applications of Exosomes in Female Medicine: A Systematic Review of Molecular Biology, Diagnostic and Therapeutic Perspectives
Systematic Review on Face & Skin, Systemic / IV, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci2 citations - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Osteogenic and Biocompatibility Potential of Polylactic Acid-Based Materials: A Systematic Review of Human Primary Cells Studies
Systematic Review on Face & Skin, published in J Funct Biomater (2026) — summary generated from the PubMed abstract.
- 2026
J Funct Biomater